Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects.
Cheng SunHao LiuZiwei OuyangJie DingQin ZhangHongjie MaDandan XuQian ZhangRenpeng ZhouMingming YangWei HuPublished in: Expert opinion on investigational drugs (2024)
The trial is registered in ClinicalTrials.gov (CT. gov identifier: NCT05504746).